{"nctId":"NCT00440557","briefTitle":"An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease","startDateStruct":{"date":"2006-09"},"conditions":["Anemia"],"count":375,"armGroups":[{"label":"TIW: Epoetin alfa 3 injections Weekly/Once Weekly","type":"EXPERIMENTAL","interventionNames":["Drug: Epoetin alfa 3 times weekly /once weekly"]},{"label":"QW: Epoetin alfa once weekly","type":"EXPERIMENTAL","interventionNames":["Drug: Epoetin alfa once weekly"]},{"label":"Q2W: Epoetin alfa once every two weeks","type":"EXPERIMENTAL","interventionNames":["Drug: Epoetin alfa once every two weeks"]}],"interventions":[{"name":"Epoetin alfa 3 times weekly /once weekly","otherNames":["PROCRIT"]},{"name":"Epoetin alfa once weekly","otherNames":["PROCRIT"]},{"name":"Epoetin alfa once every two weeks","otherNames":["PROCRIT"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Meet the diagnostic criteria for chronic kidney disease, defined as a glomerular filtration rate (GFR) more than or equal to 15 mL/min per 1.73 m2 and less than 60 mL/min per 1.73 m2 (Stages 3 and 4) as calculated by the central laboratory\n* Require support of an erythropoietin receptor agonist\n\nExclusion Criteria:\n\n* Uncontrolled hypertension\n* Serum ferritin level less than 50 ng/mL\n* Serum iron overload\n* Severe congestive heart failure\n* Active infection","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Hb Concentration (g/dL) From Baseline to the Average of the Last 8 Weeks of Treatment Through Week 22","description":"The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included in calculating the average Hb during the last 8 weeks of treatment through Week 22.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.81","spread":"0.910"},{"groupId":"OG001","value":"1.59","spread":"0.997"},{"groupId":"OG002","value":"1.27","spread":"0.906"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Participants Who Exceeded a Hb Concentration of 11.9 g/dL During First 22 Weeks of Treatment","description":"The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. participants who exceed a Hb value of 11.9 g/dL at least once were included in the numerator of the percentage calculation.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"89","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Maximum Hb Concentration (g/dL) During First 22 Weeks of Treatment","description":"The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. A maximum Hb observation was identified for each participant during the first 22 weeks of treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.87","spread":"1.176"},{"groupId":"OG001","value":"12.61","spread":"1.158"},{"groupId":"OG002","value":"12.42","spread":"1.310"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Participants Who Met or Exceeded Hb Rate of Rise >=1.0 g/dL/2 Weeks During First 22 Weeks of Treatment","description":"Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 1.0 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"119","spread":null},{"groupId":"OG001","value":"116","spread":null},{"groupId":"OG002","value":"114","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Participants Who Met or Exceeded Hb Rate of Rise >=1.5 g/dL/2 Weeks During First 22 Weeks of Treatment","description":"Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 1.5 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"85","spread":null},{"groupId":"OG002","value":"76","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Particpants Who Met or Exceeded Hb Rate of Rise >=2.0 g/dL/2 Weeks During First 22 Weeks of Treatment","description":"Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 2.0 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"51","spread":null},{"groupId":"OG002","value":"44","spread":null}]}]}]},{"type":"POST_HOC","title":"Maximum (Max) Hb Rate (g/dL/2 Weeks) of Rise During First 22 Weeks of Treatment","description":"Change is calculated as mean hemoglobin (Hb) over last 8 wks subtracts baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Max Hb RR observation was identified for each participant during the 1st 22 wks of treatment. This was the max RR in hemoglobin over any 2-wk period per participant.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.99","spread":"0.839"},{"groupId":"OG001","value":"2.02","spread":"1.008"},{"groupId":"OG002","value":"1.92","spread":"1.027"}]}]}]},{"type":"SECONDARY","title":"Participants With an Increase of â‰¥1 g/dL in Hb Concentration From Baseline by Week 9","description":"The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Hb increase is defined as the post-baseline Hb level minus the baseline Hb level.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"108","spread":null},{"groupId":"OG002","value":"106","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":123},"commonTop":["Hypertension","Hyperkalaemia","Urinary tract infection","Diarrhoea","Dizziness"]}}}